PUBLIC COMPANY
save$NKTXNkarta, Inc.
$NKTXSouth San Francisco, CA, USupdated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- phase2A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
- phase1NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
- phase1NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
🐶 Hiring Signal
Where Nkarta, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaImmunology & Inflammation 2
departmentClinical 1R&D / Discovery 1
News
no news has mentioned this company yet
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that